Accelerated fibrosis and apoptosis with ageing and in atrial fibrillation: Adaptive responses with maladaptive consequences

Experimental and Therapeutic Medicine

Volumn 5, Issue 3, 2013, Pages 723-729

  Xu, Guo Jun ^a   Gan, Tian Yi ^a   Tang, Bao Peng ^a   Chen, Zu Heng ^a   Mahemuti, Ailiman ^a   Jiang, Tao ^a   Song, Jian Guo ^a   Guo, Xia ^a   Li, Yao Dong ^a   Miao, Hai Jun ^a   Zhou, Xian Hui ^a   Zhang, Yu ^a   Li, Jin Xin ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

Ageing; Apoptosis; Atrial fibrillation; Atrial fibrosis; Structural remodeling

Indexed keywords

CEFAZOLIN; GELATINASE B; PROTEIN BAX; PROTEIN BCL 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOG; ELECTROCARDIOGRAPHY; FIBROSIS; GENE EXPRESSION; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; NICK END LABELING; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84873209229     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.899     Document Type: Article

References (38)

1. Nattel S: New ideas about atrial fibrillation 50 years on. Nature 415: 219-226, 2002.
2. Chen LY and Shen WK: Epidemiology of atrial fibrillation: A current perspective. Heart Rhythm 4: S1-S6, 2007.
3. Allessie M, Ausma J and Schotten U: Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res54: 230-246, 2002.
4. Kostin S, Klein G, Szalay Z, Hein S, Bauer EP and SchaperJ: Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 54: 361-379, 2002.
5. Everett TH, Wilson EE, Verheule S, Guerra JM, Foreman S and Olgin J: Structural atrial remodeling alters the substrate and spatiotemporal organization of AF: a comparison in canine models of structural and electrical atrial remodeling. Am J Physiol Heart Circ Physiol 291: H2911-H2923, 2006.
6. Williams GT: Programmed cell death: apoptosis and oncogenesis. Cell 65: 1097-1098, 1991.
7. Lockshin RA, Facey CO and Zakeri Z: Cell death in the heart. Cardiol Clin 19: 1-11, 2001.
8. Yang E, Zha J, Jockel J, Boise LH, Thompson CB and KorsmeyerSJ: Bad, a heterodimeric partner for bcl-XL and bcl-2, displaces bax and promotes cell death. Cell 80: 285-291, 1995.
9. Verheule S, Wilson E, Everett T IV, Shanbhag S, Golden C and Olgin J: Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation. Circulation 107: 2615-2622, 2003.
10. Spinale FG: Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 87: 1285-1342, 2007.
11. Cardin S, Libby E, Pelletier P, et al: Contrasting gene expression profiles in two canine models of atrial fibrillation. Circ Res 100: 425-433, 2007.
12. Bouzeghrane F, Reinhardt DP, Reudelhuber TL and Thibault G: Enhanced expression of fibrillin-1, a constituent of the myocardial extracellular matrix in fibrosis. Am J Physiol Heart Circ Physiol289: H982-H991, 2005.
13. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, VanWagoner DR and Bauer JA: Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation104: 174-180, 2001.
14. Disertori M, Latini R, Barlera S, et al: Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360: 1606-1617, 2009.
15. Mukherjee R, Herron AR, Lowry AS, et al: Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol 97: 532-537, 2006.
16. Anyukhovsky EP, Sosunov EA, Plotnikov A, Gainullin RZ, Jhang JS, Marboe CC and Rosen MR: Cellular electrophysiologic properties of old canine atria provide a substrate for arrhythmogenesis. Cardiovasc Res 54: 462-469, 2002.
17. Lin CS, Lai LP, Lin JL, et al: Increased expression of extracellular matrix proteins in rapid atrial pacing-induced atrial fibrillation. Heart Rhythm 4: 938-949, 2007.
18. Moe GW, Laurent G, Doumanovskaia L, Konig A, Hu X and Dorian P: Matrix metalloproteinase inhibition attenuates atrial remodeling and vulnerability to atrial fibrillation in a canine model of heart failure. J Card Fail 14: 768-776, 2008.
19. Tanaka K, Zlochiver S, Vikstrom KL, et al: The spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure. Circ Res 101: 839-847, 2007.
20. Wit AL and Boyden PA: Triggered activity and atrial fibrillation. Heart Rhythm 4: S17-S23, 2007.
21. Weiss JN, Qu Z, Chen PS, et al: The dynamics of cardiac fibrillation. Circulation 112: 1232-1240, 2005.
22. Everett TH IV and Olgin JE: Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 4: S24-S27, 2007.
23. Qu Z, Garfinkel A, Chen PS and Weiss JN: Mechanisms of discordant alternans and induction of reentry in simulated cardiac tissue. Circulation 102: 1664-1670, 2000.
24. Miragoli M, Gaudesius G and Rohr S: Electrotonic modulation of cardiac impulse conduction by myofibroblasts. Circ Res 98: 801-810, 2006.
25. Koura T, Hara M, Takeuchi S, et al: Anisotropic conduction properties in canine atria analyzed by high resolution optical mapping: preferential direction of conduction block changes from longitudinal to transverse with increasing age. Circulation105: 2092-2098, 2002.
26. Thijssen VL, Ausma J, Liu GS, Allessie MA, van Eys GJ and Borgers M: Structural changes of atrial myocardium during chronic atrial fibrillation. Cardiovasc Pathol 9: 17-28, 2000.
27. Mandapati R, Skanes A, Chen J, Berenfeld O and Jalife J: Stable microreentrant sources as a mechanism of atrial fibrillation in the isolated sheep heart. Circulation 101: 194-199, 2000.
28. Ausma J, Wijffels M, Thone F, Wouters L, Allessie M and BorgersM: Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 96: 3157-3163, 1997.
29. Olivetti G, Abbi R, Quaini F, et al: Apoptosis in the failing human heart. N Engl J Med 336: 1131-1141, 1997.
30. Hockenbery D, Nunez G, Milliman C, Schreiber RD and Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336, 1990.
31. Goodwin G, Taylor C and Taegtmeyer H: Regulation of energy metabolism of the heart during acute increase in heart work. J Biol Chem 273: 29530-29539, 1998.
32. Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programed cell death. Cell 74: 609-619, 1993.
33. Yin XM, Oltvai ZN and Korsmeyer SJ: BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369: 321-333, 1994.
34. van Bilsen M, van der Vusse G and Reneman R: Transcriptional regulation of metabolic processes: implications for cardiac metabolism. Pflügers Arch 437: 2-14, 1998.
35. Cheng EH, Kirsch DG and Clem RJ, et al: Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 278: 1966-1968, 1997.
36. Marton A, Mihalik R, Bratincsák A, et al: Apoptotic cell death induced by inhibitors of energy conservation. Eur J Biochem250: 467-475, 1997.
37. Tanaka M, Ito H, Adachi S, et al: Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res 75: 426-433, 1994.
38. Depre C, Rider M and Hue L: Mechanisms of control of heart glycolysis. Eur J Biochem 258: 277-290, 1998.